Key result
Skeletal myoblasts and bone marrow-derived stem cells showed mixed results, with the majority of studies demonstrating no significant overall improvement in left ventricular ejection fraction in heart failure patients.
Why the study?
Current heart failure regimens rely on medical therapy and transplantation, prompting evaluation of the efficacy of skeletal myoblasts and bone marrow-derived stem cells as potential treatments.
Does stem cell therapy (skeletal myoblasts and bone marrow-derived cells) improve left ventricular ejection fraction in patients with heart failure?
Does stem cell therapy (skeletal myoblasts and bone marrow-derived cells) improve left ventricular ejection fraction in patients with heart failure?
Answers are grounded in this paper and cite their sources.
Current evidence shows mixed and overall unremarkable results for the use of skeletal myoblasts and bone marrow-derived stem cells to improve LVEF in heart failure, highlighting the need for larger, standardized trials.
Heart failure is a life-threatening condition that affects millions worldwide and is only expected to get worse with an ageing population. Current treatment regimens rely on medical therapy and heart transplantation as a last resort. Stem cells have been undergoing clinical trials worldwide as a hope for a new and safe clinical treatment. Skeletal myoblasts and bone marrow-derived stem cells are two types of stem cells being tested. The objective is to evaluate the efficacy of these two types of stem cells for heart failure therapy. Data were searched in PubMed using both regular and Medical Subject Heading (MeSH) keywords (stem cells, therapy, heart failure) and then filtered using inclusion/exclusion criteria (language, species, publication date, and age). In total, 31 research articles were reviewed (14 clinical trials, four randomized control trials, nine review articles, one case report, one comparative study, one systematic review, and one categorized as a systematic review and meta-analysis). Both skeletal myoblasts and bone marrow-derived stem cells showed mixed results in improving left ventricular ejection fraction in heart failure patients in the majority of studies. Larger studies need to be done to further investigate the efficacy of stem cells as a therapy for heart failure.
No takes yet. Share an insight, caveat, or question.
Cheung et al. (2020) conducted a review in Heart failure (n=5,154). Stem cell therapy (skeletal myoblasts and bone marrow-derived cells) vs. Control or placebo (varies by included study) was evaluated on Left ventricular ejection fraction (LVEF). Skeletal myoblasts and bone marrow-derived stem cells showed mixed results, with the majority of studies demonstrating no significant overall improvement in left ventricular ejection fraction in heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: